Astellas Pharma (OTCMKTS:ALPMY) Reaches New 1-Year High – Time to Buy?

Astellas Pharma Inc. (OTCMKTS:ALPMY) reached a new 52-week high on Friday . The company traded as high as $13.69 and last traded at $13.02, with a volume of 211103 shares trading hands. The stock had previously closed at $13.2070.

Analyst Upgrades and Downgrades

ALPMY has been the subject of several analyst reports. Zacks Research cut Astellas Pharma from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 22nd. Sanford C. Bernstein downgraded Astellas Pharma from an “outperform” rating to a “market perform” rating in a report on Tuesday, September 2nd. Two analysts have rated the stock with a Hold rating, Based on data from MarketBeat, Astellas Pharma currently has an average rating of “Hold”.

Astellas Pharma Stock Performance

The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.80 and a current ratio of 1.03. The stock has a 50-day moving average price of $11.63 and a 200 day moving average price of $10.85.

Astellas Pharma (OTCMKTS:ALPMY) last issued its quarterly earnings results on Thursday, October 30th. The company reported $0.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.20 by $0.10. The company had revenue of $3.45 billion for the quarter, compared to the consensus estimate of $3.14 billion. Astellas Pharma had a return on equity of 22.21% and a net margin of 6.39%. As a group, analysts expect that Astellas Pharma Inc. will post 0.42 EPS for the current fiscal year.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.